导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 6.15% | 1141/4773 |
| 近一周 | -1.10% | 1679/5465 |
| 近一月 | -3.95% | 2922/5421 |
| 近一季 | -8.24% | 3180/5231 |
| 近半年 | -3.08% | 2385/4920 |
| 近一年 | 11.68% | 1002/4394 |
| 近两年 | 88.06% | 739/2954 |
| 近三年 | 49.51% | 566/2253 |
| 成立以来 | -7.11% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.07% 1073/4961 |
20.62% 1216/5312 |
- - |
- - |
| 2025 | 35.57% 980/4813 |
3.00% 1217/3635 |
2.45% 1557/4076 |
26.08% 1365/4524 |
1.89% 1171/4813 |
| 2024 | 9.36% 1475/3463 |
-2.80% 1436/2808 |
-5.21% 1672/3014 |
17.25% 1223/3129 |
1.23% 1100/3463 |
| 2023 | -6.45% 843/2656 |
7.90% 514/2280 |
-4.31% 1133/2385 |
-4.86% 1240/2515 |
-4.76% 1162/2655 |
| 2022 | -19.02% 789/2207 |
-14.07% 898/1919 |
3.11% 1213/2016 |
-10.99% 483/2113 |
2.69% 861/2208 |
| 2021 | 17.67% 224/1822 |
-1.11% 434/1255 |
10.22% 486/1330 |
4.41% 353/1466 |
3.40% 438/1822 |
| 2020 | 21.94% 681/1250 |
-4.29% 353/1028 |
16.79% 412/1067 |
5.96% 884/1164 |
2.96% 952/1184 |
| 2019 | 26.44% 574/1092 |
33.06% 148/754 |
-10.64% 745/804 |
0.02% 568/850 |
6.31% 628/918 |
| 2018 | -32.58% 534/834 |
- - |
- - |
- - |
-13.28% 524/691 |
| 2017 | 1.86% 447/714 |
- - |
- - |
- - |
- - |
| 2016 | -16.79% 387/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 国寿安保中证500ETF VS. 长安沪深300非周期A(740101) |